Typhoid Fever Vaccines Market to Garner US$ 554.4 Mn Threshold By 2026 – Coherent Market Insights
Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Global Typhoid Fever Vaccines Market, by Vaccine Type (Live Attenuated Vaccine, Capsular Polysaccharide Vaccines, Conjugate Vaccine, and Others), by Typhoid Fever Vaccines Type (Oral and Parental), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$ 225.0 Mn in 2018, and is estimated to exhibit a CAGR of 11.9% over the forecast period (2018-2026), as highlighted in a new report published by Coherent Market Insights.
Get FREE Sample PDF Including COVID-19 Impact Analysis: https://www.coherentmarketinsights.com/insight/request-pdf/2552
The increasing government initiatives for rising awareness about typhoid vaccines among populace and supporting access to new vaccines are the factors that are expected to drive growth of the global typhoid fever vaccines market over the forecast period. Moreover, active involvement by organizations such as GAVI Alliance (Global Alliance for Vaccines and Immunization), UNICEF (United Nations International Children’s Emergency Fund), WHO (World Health Organization), and others are increasing accessibility of these vaccines in emerging economies, which is further expected to fuel typhoid fever vaccines market growth.
For instance, GAVI designated US$ 85 million to fund introduction of Typbar TCV (Bharat Biotech) vaccine in low-income countries across Africa and Asia region, in April 2018.
Additionally, there are several typhoid conjugate vaccines present in the pipeline, which are expected to enter in the market over the forecast period. For instance, in October 2017, WHO’s Strategic Advisory Group of Experts on Immunization (SAGE) re-emphasized the importance of typhoid vaccines in low- and middle-income countries, as well as for the control of endemic typhoid.
Moreover, the Typhoid Vaccine Acceleration Consortium (TyVAC), which is a partnership between University of Maryland School of Medicine, University of Oxford and PATH, is focusing on conducting clinical trials for Typbar TCV prequalified vaccine in Malawi, Nepal, and Bangladesh to further evaluate clinical efficacy and potential of the vaccine in reducing typhoid burden in these countries.
Furthermore, introduction of clinically more effective typhoid vaccines in private markets (such as India) as well as globally is expected to drive growth of the market. For instance, Vivotif (oral vaccine), clinically more effective Typhim Vi (WHO prequalified in 2011), and now Typbar TCV (first conjugate vaccine WHO prequalified in 2017) are now available in the market.
Browse 26 Market Data Tables and 25 Figures spread through 177 Pages and in-depth TOC on Global Typhoid Fever Vaccines Market, by Vaccine Type (Live Attenuated Vaccine, Capsular Polysaccharide Vaccines, Conjugate Vaccine, and Others), by Typhoid Fever Vaccines Type (Oral and Parental), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Global Forecast to 2026
To know the latest trends and insights prevalent in the Typhoid Fever Vaccines market Press Release, click the link below: https://bit.ly/3iOzI0s
In addition, efficient antibiotic treatment have the ability to reduce the fatality rate of typhoid to less than 1%. However, in the recent past there is an increase in antimicrobial resistance of Salmonella Typhi. For instance, according to the Typhoid Vaccine Acceleration Consortium (TyVAC), a partnership between University of Maryland School of Medicine, University of Oxford and PATH, 97% of registered typhoid cases in Malawi have resisted treatment from multiple antibiotics, by 2014.
Moreover, according to the same source, the antibiotic resistant typhoid cases are increasing globally. In relation to this, in 2015, the World Health Assembly (WHA) started a global action plan to tackle drug resistance, which focuses on prevention, surveillance, and research of antibiotic resistance.
Moreover, the Wellcome Trust and current surveillance projects such as Surveillance for Enteric Fever in Asia Project (SEAP) and Severe Typhoid Fever Surveillance in Africa (SETA) are conducting researches to detect typhoid drug-resistance trends and monitor antibiotic use across South Asia and sub-Saharan Africa, which is expected to drive the market growth over the forecast period.
Key Takeaways of the Typhoid Fever Vaccines Market:
- The global typhoid fever vaccines market is expected to exhibit a CAGR of 11.9% over the forecast period (2018-2026), attributed to continuous product launches and regulatory approvals, coupled with robust pipeline of novel typhoid fever vaccines
- Among regions, Asia Pacific is expected to account for a largest market share over the forecast period, attributed to high prevalence of typhoid fever in the region. For instance, according to the data published by Medindia around 1,845,997 cases of typhoid were reported in India in 2015.
- Moreover, North America is expected to witness stagnant growth over the forecast period, attributed to low prevalence of typhoid in region. For instance, according to the data published by Centers of Disease Control and Prevention (CDC) 2017, around 300 culture-confirmed cases of typhoid fever and 80 cases of paratyphoid fever caused by S. enterica serotype Paratyphi A are reported annually in the U.S.
- Key players operating in the typhoid fever vaccines market include GlaxoSmithKline Plc., Sanofi SA, Bharat Biotech, Bio-Med Pvt. Ltd., PT Bio Farma, PaxVax, Inc. Shanghai Institute of Biological Products Co., Ltd., and Prokarium
Apply Promo Code “CMIFIRST1000” And Get Instant Discount Of USD 1000
Buy Now this Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/2552
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
This content has been distributed via CDN Newswire press release distribution service. For press release enquires please mail us at email@example.com.
- CDN Newswire